10-K: Apellis Pharmaceuticals Navigates SYFOVRE Challenges, Reports Strong Revenue Growth in 2023

Sentiment:

Annual Results 27 February 2024 7:01 AM

📋All filings for Apellis Pharmaceuticals, INC

Apellis Pharmaceuticals reports significant revenue growth driven by SYFOVRE and EMPAVELI, while addressing safety concerns and strategic pipeline adjustments in its 2023 10-K filing.

Delay expectedThe company is seeking re-examination of the marketing authorization application for SYFOVRE in the European Union, indicating a delay in potential approval.

Worse than expectedThe company reported a net loss of $528.6 million for the year ended December 31, 2023.The company experienced reports of retinal vasculitis following SYFOVRE treatment, which impacted sales.

Summary

Apellis Pharmaceuticals, a commercial-stage biopharmaceutical company, reported a net loss of $528.6 million for the year ended December 31, 2023.
The company's revenue reached $396.6 million, driven by $275.2 million from SYFOVRE sales and $91.0 million from EMPAVELI sales.
Apellis is addressing retinal vasculitis events associated with SYFOVRE, estimating an incidence rate of approximately 0.01% per injection.
The company is pursuing marketing approvals for SYFOVRE outside the U.S., with applications under review in Canada, Australia, the United Kingdom, and Switzerland.
Apellis discontinued the Phase 3 CASCADE trial for CAD due to decreased medical need and limited patient eligibility.
The company plans to report top-line data from the Phase 3 VALIANT trial for IC-MPGN and C3G in mid-2024.
Apellis is collaborating with Beam Therapeutics on gene-editing therapies and advancing APL-3007, a siRNA therapy.
The company expects cash and cash equivalents, along with revenue from EMPAVELI and SYFOVRE, to fund operations for at least the next 12 months.
A corporate restructuring in August 2023 resulted in a 25% workforce reduction, expected to yield $300 million in cost savings through 2024.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While there's strong revenue growth and progress in commercialization, the net losses, safety concerns, and pipeline adjustments temper the overall outlook.

Positives

Significant revenue growth driven by SYFOVRE and EMPAVELI sales.
FDA approval of the EMPAVELI Injector to enhance self-administration.
Positive results from the Phase 2 NOBLE trial for IC-MPGN and C3G.
Marketing applications for SYFOVRE under review in multiple countries.
Increasing treatment effects demonstrated in the GALE long-term extension trial of SYFOVRE.
EC updated Aspaveli indication to include all PNH patients with hemolytic anemia.

Negatives

Net losses of $528.6 million for the year ended December 31, 2023.
Reports of retinal vasculitis following SYFOVRE treatment impacted sales.
Negative opinion from CHMP regarding SYFOVRE marketing authorization in the European Union.
Discontinuation of the Phase 3 CASCADE trial for CAD and Phase 2 MERIDIAN study for ALS.
Dependence on third parties for manufacturing, storage, and distribution.

Risks

Commercial success of SYFOVRE and EMPAVELI is critical.
Potential for discovery of less effectiveness or new safety issues with EMPAVELI or SYFOVRE.
Need for additional funding to support operations and development programs.
Payment obligations to SFJ Pharmaceuticals Group.
Competition from other therapies and product candidates.
Reliance on third parties for manufacturing and clinical trials.
Dependence on Sobi for ex-U.S. commercialization of systemic pegcetacoplan.
Potential loss of intellectual property license rights.
Potential product liability claims.

Future Outlook

Apellis plans to continue the commercialization of SYFOVRE and EMPAVELI, advance systemic pegcetacoplan for C3G and IC-MPGN, and progress its early pipeline and Beam collaboration.

Industry Context

The announcement reflects the competitive landscape in the biopharmaceutical industry, particularly in ophthalmology and rare diseases, with a focus on complement inhibition. Apellis faces competition from established therapies and emerging treatments, requiring strategic commercialization and pipeline development.

Comparison to Industry Standards

The document mentions competitors such as Astellas Pharma Inc. with avacincaptad pegol (Izervay), AstraZeneca with eculizumab (Soliris) and ravulizumab (Ultomiris), and Novartis with iptacopan (Fabhalta).
The document references other companies developing product candidates for GA, including Annexon Biosciences, Regeneron Pharmaceuticals Inc., Alnylam Pharmaceuticals, Inc., Ionis, Roche/Genentech, AstraZeneca, The Janssen Pharmaceutical Companies of Johnson & Johnson, Alkeus Pharmaceuticals, Inc., Stealth BioTherapeutics, Inc., Belite Bio, Inc., Lineage Cell Therapeutics, Inc., Aviceda Therapeutics, Inc., and Ocugen Inc..
The document references companies developing product candidates for PNH, including Roche and Chugai Pharmaceutical Co., AstraZeneca, and Amgen Inc..

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Chief Medical Officer	NA	Caroline Baumal, M.D.	January 3, 2023	New Hire

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Compensation Recovery Policy	Adoption of Dodd-Frank Compensation Recovery Policy	October 2, 2023	The policy allows the company to recover erroneously awarded compensation from executive officers in the event of an accounting restatement.

Legal Proceedings

The company and certain of its current and former executive officers are defendants in a purported class action lawsuit alleging violations of Sections 10(b) and/or 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder by misrepresenting and/or omitting certain material facts related to the design of SYFOVREs clinical trials and the risks associated with SYFOVREs commercial adoption.

Stakeholder Impact

Shareholders: Potential for long-term growth but face risks related to clinical trials, competition, and market acceptance.
Employees: Workforce reduction in 2023, but ongoing investment in key personnel.
Patients: Access to new treatments for GA and PNH, but potential safety concerns with SYFOVRE.
Payors: Focus on cost containment and reimbursement challenges.

Next Steps

Continue commercialization of SYFOVRE and EMPAVELI.
Pursue marketing approvals for SYFOVRE outside the U.S.
Report top-line data from the Phase 3 VALIANT trial in mid-2024.
Advance early pipeline and Beam collaboration.

Key Dates

Date	Description
May 2010	Commencement of operations for Apellis Pharmaceuticals, Inc.
March 28, 2008	Date of the Patent License Agreement with The Trustees of the University of Pennsylvania (Non-ophthalmic Fields of Use)
March 28, 2008	Date of the Amended and Restated Patent License Agreement with The Trustees of the University of Pennsylvania (Ophthalmic Field of Use)
March 2008	Apellis AG entered into an agreement with Penn for an exclusive worldwide license, under specified patent rights controlled by Penn, to develop and commercialize products covered by the licensed patent rights for all fields except the treatment of ophthalmic indications.
March 2008	Penn licensed rights to the same portfolio of cases to Potentia, to develop and commercialize products covered by the licensed patent rights for the treatment of ophthalmic indications.
March 2010	U.S. Congress enacted the ACA which, among other things, includes changes to the coverage and payment for drug products under government health care programs.
September 2015	Potentia assigned the license agreement between Potentia and Penn to us in connection with our acquisition of the assets of Potentia pursuant to an asset purchase agreement with Potentia.
September 16, 2011	The Leahy-Smith America Invents Act was signed into law.
April 2013	Changes included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect.
May 2016	The EMA launched an initiative to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist.
December 2016	Congress authorized the FDA to accelerate review and approval of products designated as regenerative advanced therapies.
September 11, 2019	The Company entered into capped call transactions with two counterparties.
October 1, 2019	The Company adopted the Executive Separation Benefits and Retention Plan.
October 27, 2020	The Company entered into the Sobi collaboration agreement.
December 30, 2020	The Company entered into a commercial supply agreement with Bachem to supply the drug substance for the finished dosage form of systemic pegcetacoplan and intravitreal pegcetacoplan.
March 10, 2021	The Company entered into an amended and restated commercial supply agreement with NOF to purchase PEG, which is a component of each of systemic pegcetacoplan and intravitreal pegcetacoplan.
May 2021	Systemic pegcetacoplan was approved by the FDA with the brand name EMPAVELI for the treatment of adult patients with PNH.
June 2021	The Company entered into an exclusive five-year research collaboration with Beam focused on the use of Beams proprietary base editing technology to discover new treatments for complement-driven diseases.
December 2021	The European Commission approved systemic pegcetacoplan with the brand name Aspaveli for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months.
January 31, 2022	The new Clinical Trials Regulation (EU) No 536/2014 became effective in the European Union and replaced the prior Clinical Trials Directive 2001/20/EC.
March 2022	Aspaveli was approved in the United Kingdom.
March 2022	The FDA finalized guidance entitled Expansion Cohorts: Use in First-In-Human Clinical Trials to Expedite Development of Oncology Drugs and Biologics.
August 2022	Amgen announced that a Phase 3 trial evaluating ABP959 met its primary endpoints.
August 2022	The Inflation Reduction Act of 2022 was signed into law by President Biden.
December 2022	The Company submitted an MAA to the EMA for intravitreal pegcetacoplan for the treatment of GA.
December 2022	Congress required sponsors to develop and submit a diversity action plan for each phase 3 clinical trial or any other pivotal study of a new drug or biological product.
February 2023	Intravitreal pegcetacoplan was approved by the FDA with the brand name SYFOVRE for the treatment of adult patients with GA secondary to AMD.
March 2023	The Company launched SYFOVRE in the United States.
June 2023	The FDA issued draft guidance with updated recommendations for GCPs aimed at modernizing the design and conduct of clinical trials.
July 2023	The Company disclosed that it had received reports of a small number of events of retinal vasculitis following SYFOVRE treatment.
August 2023	Astellas Pharma Inc. received FDA approval for avacincaptad pegol (marketed as Izervay) for the treatment of GA.
October 1, 2023	The U.S. Centers for Medicare & Medicaid Services assigned a permanent and product-specific J-code for SYFOVRE, which became effective.
October 2023	The Company announced the FDA approval of the EMPAVELI Injector.
October 2023	The Company announced positive results from ten patients treated in the Phase 2 NOBLE trial investigating pegcetacoplan for the treatment of post-transplant recurrence of primary IC-MPGN and C3G.
November 2023	The Company disclosed data from GALE, its long-term extension trial of SYFOVRE, which demonstrated increasing treatment effects over 36 months in patients with GA.
November 2023	The Company updated the U.S. Prescribing Information, or USPI, for SYFOVRE in collaboration with the FDA to include the events of retinal vasculitis with or without occlusion as part of the Warnings and Precautions and Adverse Reactions Postmarketing Experience sections of the USPI.
December 2023	The FDA approved iptacopan, which is marketed by Novartis AG, or Novartis, for the treatment of adults with PNH.
January 2024	The Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency adopted a negative opinion on the marketing authorization application, or MAA, for SYFOVRE in the European Union.
January 2024	The EC updated the Aspaveli indication statement to include all PNH patients with hemolytic anemia.
January 2024	The Company and Sobi agreed to discontinue the CASCADE Phase 3 trial evaluating systemic pegcetacoplan in patients with cold agglutinin disease, or CAD.
Mid-2024	The Company plans to report top-line data from the ongoing Phase 3 VALIANT trial investigating pegcetacoplan in adolescent and adult patients with native and post-transplant recurrence IC-MPGN and C3G.

Keywords

SYFOVRE, EMPAVELI, Pegcetacoplan, Geographic Atrophy, Paroxysmal Nocturnal Hemoglobinuria, C3G, IC-MPGN, Sobi, Retinal Vasculitis, Clinical Trials, FDA, Revenue, Pharmaceuticals, Biopharmaceutical, Rare Disease

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.